Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after "booster" dose of COVID-19 vaccine.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
28
03
2023
received:
14
02
2023
accepted:
04
04
2023
medline:
14
6
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
Since vaccines against COVID-19 are available, it has been debated if immunosuppressed patients with autoimmune blistering diseases (AIBDs) should be advised to interrupt the immunosuppressive therapy before receiving the vaccine, with consequent risk to experience a flare of disease. In the present study, we measured the neutralizing antibodies production after anti-SARS-CoV-2 vaccination in patients with AIBDs on immunosuppressive treatment, compared to healthy controls. Our results give strength to the hypothesis that these patients do not need to discontinue their therapy to produce effective levels of neutralizing antibodies, in other words to achieve successful protection.
Substances chimiques
COVID-19 Vaccines
0
Immunosuppressive Agents
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
News
Langues
eng
Sous-ensembles de citation
IM
Pagination
847-849Informations de copyright
© 2023 the International Society of Dermatology.
Références
Kasperkiewicz M, Schmidt E, Amagai M, Fairley JA, Joly P, Murrell DF, et al. Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35:e412-4.
Cozzani E, Gasparini G, Sticchi L, Russo R, Icardi G, Parodi A. Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases. Eur J Dermatol. 2021;31:415-7.
Maronese CA, Di Zenzo G, Genovese G, Barei F, Monestier A, Pira A, et al. Reply to “New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin”. Dermatol Ther. 2022;35:e15496.
Maronese CA, Caproni M, Moltrasio C, Genovese G, Vezzoli P, Sena P, et al. Bullous Pemphigoid Associated With COVID-19 Vaccines: an Italian Multicentre Study. Front Med (Lausanne). 2022;9:841506.
Damiani G, Pacifico A, Pelloni F, Iorizzo M. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? J Eur Acad Dermatol Venereol. 2021;35:e645-7.
Afacan E, Edek YC, Ílter N, Gülekon A. Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center. Int J Dermatol. 2022;61:626-7.
Cozzani E, Gasparini G, Russo R, Parodi A. May bullous pemphigoid be worsened by COVID-19 vaccine? Front Med (Lausanne). 2022;9:931872.
Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol. 2021;18:2293-306.
Pang NYL, Pang ASR, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Med Res. 2021;8:47.
Mohebi F, Tavakolpour S, Teimourpour A, Toosi R, Mahmoudi H, Balighi K, et al. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies. BMC Dermatol. 2020;20:13.
Fenizia C, Moltrasio C, Ottobrini L, Utyro O, Genovese G, Vanetti C, et al. SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris. J Invest Dermatol. 2023. https://doi.org/10.1016/j.jid.2022.12.023 Epub ahead of print.
Avallone G, Cavallo F, Astrua C, Caldarola G, Conforti C, de Simone C, et al. Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience. J Eur Acad Dermatol Venereol. 2022;36:e876-9.